EGFR and non-small cell lung carcinoma: Both the European Society of Medical Oncology (ESMO) (2) and the American College of Chest Physicians (ACCP) (3) recommend first-line treatment with a TKI (erlotinib or gefitinib) in metastatic NSCLC bearing an activating EGFR mutation because of higher response rate, longer progression free survival (PFS), and better quality of life when compared with first-line chemotherapy.